2025 Poster Presentations

Poster Awards will be announced Tuesday at 4:00 pm and Thursday at 12:45 pm.

Poster Session A: Monday-Tuesday

A01: Advanced Flow Cytometry Platforms for Comprehensive Monitoring in Cell Therapy: From Early Research to CMC, Presented by Yingjie L., ACROBiosystems

A02: Innovative Mycoplasma Detection Technologies: Enhancing Biopharmaceutical Safety and Efficiency, Presented by Cody W., ACROBiosystems

A03: Surfactant Stress to Stability: A Novel and Complete Characterization of Polysorbate Degradation, Presented by Wendi H., Agilent Technologies

A04: Automated Bio-Analytics for Antibody Titer and Aggregation Analysis, Presented by Tayler-Shea B., Beckman Coulter

A05: Advancing Plasmid DNA Purification Using a Next-Generation Monolithic IEX Chromatography Media, Presented by Chervee H., Biochromatographix

A06: In-Line Detergent Virus Inactivation for Continuous Processing, Presented by Jennifer Z., Biogen

A07: MauriceFlex Fractionation of Charge Variants Accompanied by LC-MS and Digital SPR Analysis Correlates Structure to the Function of a mAb, Presented by Gargi C., Bio-Techne

A08: Fast-Tracking Vaccine Manufacturing: CEPI’s Rapid Response Framework for the 100 Days Mission, Presented by June K., CEPI, the Coalition for Epidemic Preparedness Innovations

A09: The Challenge of Comparability: The Benefit of Common Release Standards for Serratia Marcescens Endonucleases, Presented by Raphael G., c-LEcta

A10: TFF in RNA Workflow: Process Optimization for RNA and LNP Manufacturing, Presented by Divakara U., Cytiva

A11: Unveiling the Complementary Benefits of Cas-CLOVER Dimeric Nuclease and Harbor-IN License Free Transposase, Presented by Christian C., Demeetra

A12: Clone Selection from Un-Purified Samples, Presented by Travis M., Fida Biosystems

A13: AI-Assisted Virtual Reality Learning Experience for Batch Bioreactor Operations, Presented by Satyanarayan D., Florida A&M University

A14: Structured Knowledge Management Platform for Bioprocess Development, Presented by Shivai G., Genedata, Inc.

A15: Maximizing Efficiency and Predictability in Bioprocess Development Using a Versatile “inGenius®” Platform, Presented by Masha K., Ingenza Ltd.

A16: Engineering and Physicochemical Characterization of REGULGENT™: A Novel Symmetric Bispecific Antibody, Presented by Seiji S., Kyowa Kirin Co., Ltd.

A17: A Novel Assay that Reveals Single-Cell Kinetic Changes in T-Cell Protein Expression During Activation, Presented by Sheldon K., LASE Innovation, Inc.

A18: Quantitative Predictive Cellular Analytics Driving Improvements in Advanced Therapy Development and Manufacturing, Presented by Jonathan T., LumaCyte

A19: Assessment of Biophysical Tools to Enable Novel Nanoemulsion Formulation Development, Presented by Donald K., Merck & Co., Inc.

A20: Digitalization of In-Process Analytical Single-Use Sensors, Presented by Jean-Nicolas A., Mettler-Toledo

A21: Optimization and Scale-up of Suspension Vero Cell Culture Technology towards Industrial Applications in Cost-effective Production of Viral Vaccines and Therapeutic Viruses, Presented by Chun Fang S., National Research Council Canada

A22: Turn Flasks into Bioreactors: Increase Antibody Titers in Flasks with Automated Continuous Feeding, Presented by Michael M., ProAnalytics

A23: Comparative Assessment of Frozen Storage Container and Formulation for rAAV8 Bulk Drug Substance Manufacturing, Presented by Yu-Chieh C., Regeneron Pharmaceuticals

A24: Propionic Acid Can Serve as a Novel Marker to Quantify Poloxamer 188 Oxidative Degradation, Presented by Jing W., Regeneron Pharmaceuticals

A25: Tailoring icIEF Method Development Strategy for an "Atypical" mAb, Presented by Richa B., Rentschler Biopharma

A26: Application of Gene Editing Technologies to Improve Biotherapeutic Manufacturing, Presented by Austin H., Revvity, Inc.

A27: Analytical Methods to Evaluate RNA Circularization Efficiency, Presented by Yali S., Revvity, Inc.

A28: Developability Assessment of CD28 Costimulatory Bispecific Antibodies for the Treatment of Bladder Cancer, Presented by Soumili C., Rondo Therapeutics

A29: Development of a Robust Affinity Chromatography Process for a Novel AAV9 Capsid, Presented by Hui J., Sanofi

A30: Targeted Optimization of AAV8 Upstream Process for Enhanced Downstream Performance, Presented by Petra D., Sartorius BIA Separations

A31: End-to-End Process for Improved Purity, Combined with Innovative Analytics of LNP-Based Therapeutics, Presented by Nejc P., Sartorius BIA Separations

A32: C-Flow: A Scalable, Continuous Fermentation Platform for High-Yield E. coli Bioproduction, Presented by Charles L. & David F., Scarab Genomics LLC

A33: Analytical Testing Strategies for Complex Raw Materials Used in the Fermentation of Bacterial Strains for the Production of Live Biotherapeutic Products, Presented by Rajarshi G., Seres Therapeutics

A34: Enhancing Flow Cytometry Assay Performance with Synthetic Cell Mimics Controls for Immune Cell Profiling and Quality Control, Presented by Swetha G., Slingshot Biosciences

A35: TruCytes Potency Cell Mimics Induce Robust and Reproducible Specific Activation of CAR-T Cells, Presented by Robyn H., Slingshot Biosciences

A36: New Bioprocess Strategy with Fiber Chromatographic Clarification Platform from Discovery to Manufacturing, Presented by James M., Solventum

A37: CurigenX: Multimodal LLMs Automate CMC Documentation to Accelerate Bioprocess Scale-Up, Presented by Mo B., Stanford University

A38: From Clues to Conclusions: Investigating Polysorbate Degradation Pathways with Integrative Analytical Tools, Presented by Michal R., ten23 health

A39: Improving Time to Result: Leveraging Rapid Mycoplasma Detection and Sterility Testing in Cell Therapy Manufacturing, Presented by Sherry W., Thermo Fisher Scientific

A40: Next-Generation Protein A Resin for Enhanced Antibody Capture, Presented by Jennifer J., Tosoh Bioscience

A41: Spectroscopic Dialysis Monitoring: Results for Various Biologics, Presented by William H., Tulane University

A42: Spectroscopic Dialysis and Related Cuvette-Based Capabilities for Characterizing Biologics and Their Stability, Presented by Curt J., Tulane University

A43: Lessons Learned from PPQ-Enabling Process Characterization of UX701, a Pinnacle PCL™ rAAV Gene Therapy for Wilson Disease, Presented by Dennis P., Ultragenyx Pharmaceutical, Inc.

A44: Improved Testing Throughput by End-to-End Automation for 384 Well hcDNA qPCR Assay, Presented by Dennis G., Ultragenyx Pharmaceutical, Inc.

A45: Extended Characterization of PEIpro as a Critical Raw Material for rAAV Upstream Manufacturing Process Using HEK293-Based Transfection System, Presented by Kostantinos K., Ultragenyx Pharmaceutical, Inc.

A46: Comparison of Adeno-Associated Virus (AAV) Full and Empty Particle Separation Platforms, Presented by Jack R., Ultragenyx Pharmaceutical, Inc.

A47: Improving Recombinant Antibody Production Using FcBAR: An In Situ Approach to Detect and Amplify Protein-Protein Interactions, Presented by Mina W., University of California, San Diego

A48: Analytical and Preformulation Characterization Studies of a Recombinant Adeno-Associated Virus (rAAV) Vector-Based Vaccine Candidate to Enable Future Formulation Development, Presented by Michael W., University of Kansas, Lawrence

A49: Advances in Downstream PAT for Biologics, Vaccines and Gene Vectors, Presented by Nick P., Waters | Wyatt Technology

A50: High Sensitivity Titer & Simplified 2D Protein A-SEC Analysis for Faster Quantitation of mAb Titers and Aggregates, Presented by Emery D., Waters Corporation

A51: High Throughput Characterization of Subvisible Contamination in Protein Therapeutics, Presented by Karessa W., Waters Corporation

A52: Applying Statistical Tools for Characterization and Validation of Novel Process Control and Product Release Analytics, Presented by William J., WEJ Cell and Gene Therapy Consulting Services, LLC

Poster Session B: Wednesday-Thursday

B01: Constructing an Adaptable Cell Media Formulation for Specific Immune Cell Subpopulation Culture, Presented by Rachel D., ACROBiosystems

B02: Accelerating Lentivirus Process Development with Fast, Precise Titer Determination, Presented by Poorni A., Advanced BioScience Labs, Inc.

B03: Accelerated cGMP Production of Near-Native HIV-1 Env Trimers Following Electroporation Transfection and Immunogenicity Analysis, Presented by Elena G., Advanced BioScience Labs, Inc.

B04: Optimizing Automated Concentration for Islet Cell Production Using CTS Rotea Counterflow Centrifugation, Presented by Martha F., Advanced Regenerative Manufacturing Institute

B05: Screening and Evaluation of Several Cation Exchange (CEX) Resins for VHH Bispecific Purification to Enable Better Facility Fit- A Case Study, Presented by Nivethitha S., Alexion Pharmaceuticals, Inc., a subsidiary of AstraZeneca

B06: High Throughput Fibro PrismA and Autosampler for Upstream Purification Support, Presented by Dennis T., Alexion Pharmaceuticals, Inc., a subsidiary of AstraZeneca

B07: Liter-Scale Process for High-Quality Human PSC-Derived Pancreatic Islet Manufacturing, Presented by Yi Z., ALIT Lifetech, Inc.

B08: In-line LSPR-Based Detection of IgG Aggregates During Affinity Chromatography, Presented by Thuy T., ArgusEye AB

B09: Effects of Variable Pressure Conditions on Viral Clearance With Planova™ Filters, Presented by Mike B., Asahi Kasei Bioprocess America

B10: Implementing Virus Filtration to Ensure Pathogen Safety of Cell and Gene Therapy Products, Presented by Tomoki I., Asahi Kasei Bioprocess America

B11: State-of-the-Art Construction of IDB Digital Twins for Smart Biomanufacturing, Presented by Tianxin Z., AstraZeneca

B12: Genome-Wide Mapping of CRISPR-Cas Off-Target Cleavage Sites via GUIDE-Seq, Presented by Jimmy G., Avance Biosciences, Inc.

B13: Digitally Secure Sequencing: Implementing Part 11-Ready NGS Data Security in a CRO Environment, Presented by Apurva V., Avance Biosciences, Inc.

B14: Automating an Adeno-Associated Virus (AAV) Functional Assay Using the Biomek i7 Liquid Handler With Integrated Vi-CELL BLU Analyzer, Presented by Amy H., Beckman Coulter

B15: Pink Colored Intermediate Pool Caused by Vitamin B12 and Antibody Reduction-A Case Study and Solution, Presented by Yujie Z., BeOne Medicine(BeiGene) Ltd.

B16: Advances in Characterization and Comparability of Brazilian Biosimilar Candidates Using State-of-the-Art Analytical Technologies, Presented by Luciana M., Bio Manguinhos

B17: Optimizing Biologics Purification: Enhancing Yield and Purity with a Weak AEX-HIC Mixed-Mode Chromatography Resin, Presented by Young L., Bio-Rad Laboratories, Inc.

B18: Purification of Bivalent Bispecific Antibodies and Associated Fragments using a Cation Exchange Resin, Presented by Ankita S., Bio-Rad Laboratories, Inc.

B19: Scalable Purification with Prepacked Ceramic Hydroxyapatite Process-Scale Chromatography Columns, Presented by Renee S., Bio-Rad Laboratories, Inc.

B20: Ultra-Large-Scale 30kL Low-Cost Biologic Manufacturing, Presented by Chi-Ming Y., Boston Institute of Biotechnology

B21: High Salt, High Impact: An Endonuclease Engineered for High-Efficiency DNA Removal in Viral Vector Manufacturing, Presented by Jose V., c-LEcta

B22: Optimizing Poloxamer 188 for CHO and HEK Suspension Cells for Reduced Batch-to-Batch Variation, Presented by Mauricio P., Croda, Inc.

B23: Systematic Assessment and Development of Gamma-Retroviral Vectors Downstream Process for CAR-T and TIL Therapies, Presented by Forrest K., CTMC

B24: Fixed-Bed Bioreactor Process Development for Scalable Production of Lentiviral and Gamma-Retroviral Vectors for CAR-T and TIL Therapies, Presented by Subhashini R., CTMC

B25: Achieving Solvent/Detergent Viral Inactivation Using a Novel BSL-1 Compatible RVLP, Presented by David C., Cygnus Technologies

B26: The Impact of Elution pH on Product Quality of Fc-Containing Proteins, Presented by Jessay D., Ecolab Life Sciences

B27: An Environmentally Friendly Alternative to Triton™ X-100 for Viral Therapy Production, Presented by Yawen T., Evonik Corporation

B28: High-Throughput Mass Spectrometry Analytics for ML/AI-Ready Drug Discovery, Presented by Annie G., Genedata, Inc.

B29: Overcoming Barriers to Adopting Protein A Membrane Affinity Technology by Demonstrating Capture Step Similarity, Presented by Jeffrey C., W. L. Gore & Associates

B30: Addressing Amino Acid Misincorporation in Therapeutic Proteins Through Multivariate Analysis, Presented by Pushpraj R., Johnson & Johnson Innovative Medicine

B31: An Automated Platform for Data-Rich Experimentation for Lipid Nanoparticle Synthesis, Presented by Cedric D., Massachusetts Institute of Technology

B32: An Automated Platform for Manufacturing Nanoparticles for Drug Delivery Applications, Presented by Aniket U., Massachusetts Institute of Technology

B33: A Scalable Machine Learning-Based Platform for Absolute Quantitation of Metabolites to Elucidate CHO Cell Metabolism, Presented by Adi K., Matterworks

B34: Leveraging Novel Process Controls and Design of Experiment Studies to Improve Yeast Fermentation for a Recombinant Protein Vaccine, Presented by Katherine F., Merck & Co., Inc.

B35: Analytics at the Forefront: Utilizing mAb Fractionation to Reduce Membrane Fouling, Presented by Derek S., MilliporeSigma

B36: Affinity Based Purification of Hyaluronidase by Using Precision X® Ligands, Presented by Josephine H., Navigo Proteins GmbH

B37: Optimizing LVV Sterile Filtration: Small Scale Evaluation of Material of Construction, Effective Filter Size, and Flow Rates, Presented by Hasan Y., Novartis Gene Therapies

B38: Increasing AAV Productivity: Upstream Process Optimization for a Robust, Plug-and-Play Platform, Presented by Shannon F., Oxford Biomedica

B39: ProCel® Biome Growth, a Yeast-Based Nutrient Developed to Support Faecalibacterium prausnitzii Growth, Presented by Daniel N., Procelys by Lesaffre

B40: A Design Framework for Optimizing Ligand Spatial Arrangement in Affinity Membranes, Presented by Riddhi B., Rensselaer Polytechnic Institute

B41: Peptide Affinity Ligands for Scalable mRNA Purification: Capturing the mRNA at 5’cap, Presented by Mengyang H., Rensselaer Polytechnic Institute

B42: Guiding the Design of Affinity Membranes for Improved Selectivity: Direct Force Measurements Between mRNA and Peptide Ligands, Presented by Surya K., Rensselaer Polytechnic Institute

B43: Tuning Hydrogen Bonds and Electrostatics with Convection for Purifying mRNA: A Paradigm Shift, Presented by Thomas N., Rensselaer Polytechnic Institute

B44: Leveraging Deployable Process Analytical Technology (PAT) Solutions for Data Driven Process Intensification Through Continuous Monitoring and Control of Upstream Bioprocesses, Presented by Nick R., Repligen Corporation

B45: Plasmid Purity Testing and Conformational Analysis Using the LabChip™ GX Touch Platform, Presented by James W., Revvity, Inc.

B46: Ambr® 250 High Throughput Generation 2: A New Standard for Small Scale Bioreactors, Presented by Ellen L., Sartorius

B47: Cutting Contaminants and Costs: Impact of Nuclease Elimination from a Model AAV Bioprocess Using Chromatographic Fibers for Clarification, Presented by Nihmotullahi A., Solventum

B48: Virus Retention Assurance of IsoBlock VF, a Novel Parvovirus Retentive Filter, Through a Multi-Stage Testing Strategy, Presented by Markus M., TeraPore Technologies, Inc.

B49: Automated CAR-T Cell Manufacturing: Rapid Activation, Transduction, and Expansion in a Hollow-Fiber System, Presented by Henri J., Terumo BCT

B50: Characterization and Identification of Unknown Particulate Matter in Cell Culture Medium, Presented by Daniel M., Thermo Fisher Scientific

B51: A Streamlined and Automated Solution for CAR-T Manufacturing Using CTS™ Detachable Dynabeads™ CD4, CD8 and CD3/CD28 Magnetic Beads, Presented by Aicha Q., Thermo Fisher Scientific

B52: Innovative Capture Purification Solutions for Therapeutic Antibody Manufacturing, Presented by Eugene S., Thermo Fisher Scientific

B53: Comparison of Thomson Optimum Growth® 7L Flasks vs Ambr® 250 Bioreactor Systems Using Stable CHO Cells, Presented by Sam E., Thomson Instrument Company

B54: 21-Fold Increase in Plasmid Production Yield Compared to Traditional Methods, Presented by Jordan L., Thomson Instrument Company

B55: Thomson 7L Flask Replacing Bioreactor and Cell Bags Between 5L to 6L/Flask - Ability to Grow up to 35L/Shaker, Presented by Joseph O., Thomson Instrument Company

B56: Canola Meal Isolate (CMI): A Scalable, and Cost-Effective Albumin Replacement, Presented by John Y., Tufts Center for the Study of Drug Development

B57: Integrating Veeva Quality with PowerBI: A Digital Transformation Approach for Document Lifecycle Insights, Presented by Robert G., Ultragenyx Pharmaceutical, Inc.

B58: Enhancing Bioprocess Development Through Automated Spent Media and Titer Analysis by LC-MS with Data Connectivity via Statistical Software, Presented by Mark W., Waters Corporation

B59: COF Nano-Nets for Rapid RNA Diagnostics, Presented by Sang J., Yeungnam University